Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AVITA Medical (AVHHL) Other Non Operating Income (2019 - 2025)

Historic Other Non Operating Income for AVITA Medical (AVHHL) over the last 7 years, with Q4 2025 value amounting to $20000.0.

  • AVITA Medical's Other Non Operating Income rose 10934.58% to $20000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.0 million, marking a year-over-year decrease of 49467.68%. This contributed to the annual value of -$1.0 million for FY2025, which is 49318.18% down from last year.
  • According to the latest figures from Q4 2025, AVITA Medical's Other Non Operating Income is $20000.0, which was up 10934.58% from -$2.8 million recorded in Q3 2025.
  • AVITA Medical's 5-year Other Non Operating Income high stood at $6.3 million for Q4 2023, and its period low was -$2.8 million during Q3 2025.
  • For the 5-year period, AVITA Medical's Other Non Operating Income averaged around $453947.4, with its median value being $28000.0 (2022).
  • In the last 5 years, AVITA Medical's Other Non Operating Income surged by 535000.0% in 2022 and then plummeted by 109848.48% in 2025.
  • Over the past 5 years, AVITA Medical's Other Non Operating Income (Quarter) stood at $16000.0 in 2021, then surged by 3556.25% to $585000.0 in 2022, then surged by 984.1% to $6.3 million in 2023, then plummeted by 103.37% to -$214000.0 in 2024, then skyrocketed by 109.35% to $20000.0 in 2025.
  • Its Other Non Operating Income was $20000.0 in Q4 2025, compared to -$2.8 million in Q3 2025 and $2.5 million in Q2 2025.